April 17, 2019
BioPharmaceutical Technology Center
5445 East Cheryl Parkway
Fitchburg/Madison, WI 53711
www.btci.org

Overview
The Symposium is coordinated by the BTC Institute and the Stem Cell & Regenerative Medicine Center at the University of Wisconsin-Madison. It brings together leading researchers in immunotherapies and stem cell biology. The presentations will highlight advances in immunotherapies as well as efforts to understand and overcome immunological barriers to cell-based therapies.

Highlighted Issues
- Describing translational uses for human pluripotent stem cell-derived and MSC-derived immune therapies
- Advancing natural killer cell-based immunotherapies
- Identifying and overcoming immunological barriers for human pluripotent stem cell-based therapies
- Exploring bioengineering approaches for immunological modulation

Speakers
Achieving Durable Immune Tolerance of Curative Pluripotent Stem Cell Therapies in the Absence of Immunosuppressive Drugs
Matthew E. Brown, Ph.D., Assistant Scientist, Department of Surgery, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI

Who is Orchestrating Repair—Immune Cells or Stem Cells?
Jennifer Elisseeff, Ph.D., Morton Goldberg Professor; Wilmer Eye Institute and Biomedical Engineering, Translational Tissue Engineering Center; Board of Maryland’s Technology Development Corporation (TEDCO), Johns Hopkins Biomedical Engineering, Baltimore, MD

Multipotent Adult Progenitor Cells Suppress T Cell Activation in vivo
Karen English, Ph.D., Lecturer, Postgraduate Coordinator; Biology Department, Maynooth University, Ireland

MSC Therapies to Mitigate Tissue Injury and Inflammation
Jacques Galipeau, M.D., Professor; Hematology/Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI

Improved Cancer Therapy Using Engineered Human Pluripotent Stem Cells
Dan Kaufman, M.D., Ph.D., Professor of Medicine, Division of Regenerative Medicine, Director of Cell Therapy, University of California-San Diego, San Diego, CA

Off-the-Shelf iPS-Derived NK Cells to Treat Cancer
Jeffrey Miller, M.D., Professor of Medicine, Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN

Immune Rejection of Allogeneic Cell Transplants Derived from iPSCs is Prevented by Genetic Engineering
Sonja Schrepfer, M.D., Ph.D., Associate Professor of Surgery, Biomedical Sciences Graduate Program, University of California-San Francisco, San Francisco, CA

Biomaterials Strategies to Promote Brain Repair After Stroke
Tatiana Segura, Ph.D., Professor of Biomedical Engineering, Duke University, Raleigh, NC

Poster Contest & Poster Session Included!
Learn more, and register to join us in April:
www.btci.org